<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867332</url>
  </required_header>
  <id_info>
    <org_study_id>11007965940</org_study_id>
    <nct_id>NCT02867332</nct_id>
  </id_info>
  <brief_title>PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.</brief_title>
  <official_title>A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cell Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of PD-1 knockout engineered T cells in treating
      metastatic advanced renal cancer. Blood samples will also be collected for research purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-escalation study of ex-vivo knocked-out, expanded, and selected PD-1
      knockout-T cells from autologous origin. Patients are assigned to 1 of 3 treatment groups to
      determine the maximal tolerant dose. After the lower number of cycles are considered
      tolerant, an arm of the next higher number of cycles will be open to next patients.
      Biomarkers and immunological markers are collected and analyzed as well.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients</measure>
    <time_frame>Dose Escalation - Approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate:Response will be evaluated according to RECIST v1.1</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to average 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival - OS</measure>
    <time_frame>The time from randomization to death from any cause, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood circulating tumor DNA</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Interleukin-2 change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Interferon-γ change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Interleukin-6 change in the peripheral blood</measure>
    <time_frame>Baseline and 1 month and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparable group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-1 Knockout T Cells</intervention_name>
    <description>PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).</description>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_label>Comparable group</arm_group_label>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).</description>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_label>Comparable group</arm_group_label>
    <other_name>Interleukin-2 (IL-2)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically verified stage IV Renal cancer with measurable lesions (On CT: longest
             diameter of tumoral lesion &gt;=10 mm, shorted diameter of lymph node &gt;=15 mm; measurable
             lesions should not have been irradiated)

          -  Progressed after all standard treatment

          -  Performance score: 0-1

          -  Expected life span: &gt;= 6 months

          -  Toxicities from prior treatment has resolved. Washout period is 4 weeks for
             chemotherapy, and 2 weeks for targeted therapy

          -  Major organs function normally

          -  Women at pregnant ages should be under contraception

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Pathology is mixed type

          -  Emergent treatment of tumor emergency is needed

          -  Poor vasculature

          -  Coagulopathy, or ongoing thrombolytics and/or anticoagulation

          -  Blood-borne infectious disease, e.g. hepatitis B

          -  History of mandatory custody because of psychosis or other psychological disease
             inappropriate for treatment deemed by treating physician

          -  With other immune diseases, or chronic use of immunosuppressants or steroids

          -  Compliance cannot be expected

          -  Other conditions requiring exclusion deemed by physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yinglu Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wujiang Liu, MD and PhD</last_name>
    <phone>861083575825</phone>
    <email>liuwujiang@bjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Jin, MD and PhD</last_name>
    <phone>861083575811</phone>
    <email>jinjie@vip.163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 Apr;100:88-98. doi: 10.1016/j.critrevonc.2016.02.001. Epub 2016 Feb 10. Review.</citation>
    <PMID>26895815</PMID>
  </reference>
  <results_reference>
    <citation>Koshkin VS, Rini BI. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016 Jun;17(9):1225-32. doi: 10.1080/14656566.2016.1182987. Epub 2016 May 23. Review.</citation>
    <PMID>27112171</PMID>
  </results_reference>
  <results_reference>
    <citation>Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13.</citation>
    <PMID>27085692</PMID>
  </results_reference>
  <results_reference>
    <citation>Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol. 2014 Mar;15(1):137-46. doi: 10.1007/s11864-013-0268-y. Review.</citation>
    <PMID>24504486</PMID>
  </results_reference>
  <results_reference>
    <citation>Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther. 2013 Jun;13(6):911-25. doi: 10.1517/14712598.2013.778970. Epub 2013 Apr 16. Review.</citation>
    <PMID>23586712</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Yinglu Guo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>plan to do</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

